PPARD and metabolic syndrome: It is considered to be a “balanced” pan agonist that activates all PPARα/δ/γ at comparable doses and improves dyslipidemia via its actions against PPARα; insulin sensitivity via its actions against PPARγ, and overweightness by enhancing fatty acid oxidation, energy consumption, and adaptive thermogenesis via its actions against PPARδ [29].